AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read

Levy Raphi sold $43K of DRTS

Levy Raphi (Chief Financial Officer) sold 2,871 shares of Alpha Tau Medical Ltd. (DRTS) at $15.00 on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Levy Raphi
Published Aug 25, 2026, 2:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 3:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$DRTS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

The transaction represents a modest $43K divestiture, unlikely to move the stock.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

potential future 10b5-1 sales could accumulate

Relevance 2/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing reports a CFO's open‑market sale of 2,871 shares of Alpha Tau Medical Ltd.

Market effects

Sector

minimal impact on medical device sector

Regional

none

Global

none

Counterpoint

What could challenge this read

sale size is trivial; may not signal insider concern

Key entities

  • Company
    Alpha Tau Medical Ltd.

    Medical device company, ticker not confirmed as US‑listed

  • Insider
    Levy Raphi

    Chief Financial Officer of Alpha Tau Medical

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DRTS insider trading history →

Related articles

OCT 19
$DRTSHighAI 9/10

FDA Greenlights Expansion of Alpha Tau’s Brain Cancer Trial, With New Data Weeks Away (NASDAQ: DRTS) By FinanceWire

Alpha Tau Medical (NASDAQ: DRTS) received FDA approval to expand its U.S. brain cancer trial, doubling enrollment to 20 patients. The company will present updated REGAIN trial data on November 13, including new measures like progression-free survival and quality of life. Alpha DaRT technology aims to treat recurrent glioblastoma with localized radiation.

investing.com2 min
OCT 19
$DRTSMedAI 8/10

FDA expands Alpha Tau glioblastoma trial to 20 patients

Alpha Tau Medical (NASDAQ:DRTS) received FDA approval to expand its REGAIN trial for recurrent glioblastoma, increasing enrollment to 20 patients and adding new endpoints. The trial, presented at the Society for Neuro-Oncology Annual Meeting, evaluates the safety and feasibility of Alpha DaRT therapy. Alpha Tau's treatment is not yet approved for commercial use.

investing.com2 min
SEP 15
$DRTSHighAI 9/10

Alpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next.

Alpha Tau Medical (NASDAQ: DRTS) reported strong results from cancer trials, including a 100% response rate in head and neck cancer and promising data in brain and pancreatic cancers. The company expects key data readouts in late 2026 and early 2027, which could impact its trajectory. Alpha Tau has $104.8 million in cash and a U.S. commercialization partnership with Tolmar.

investegate.co.uk3 min
JUL 21
$DRTSMedAI 8/10

Alpha Tau Shows 100% ORR With Alpha DaRT Plus Keytruda In Head And Neck Squamous Cell Carcinoma

Alpha Tau Medical (DRTS) reported positive early clinical results for Alpha DaRT plus pembrolizumab (Keytruda) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma. In nine evaluable patients, the company said ORR was 100% with 44% complete responses and median overall survival of 18.2 months. DRTS shares closed at $13.47.

rttnews.com4 min